Cardio Diagnostics Holdings, Inc. Research and Development Expense
Cardio Diagnostics Holdings, Inc. (CDIO) reported Research and Development Expense of $162.93 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- Cardio Diagnostics Holdings, Inc. research and development expense for the quarter ending 2026-06-30 was $162.93K, a 8.74% decline year-over-year.
- Cardio Diagnostics Holdings, Inc. research and development expense for the quarter ending 2026-03-31 was $129.78K, a 9.25% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. research and development expense for the quarter ending 2025-12-31 was $286.87K, a 40.21% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. research and development expense for the quarter ending 2025-09-30 was $189.05K, a 3502.99% increase year-over-year.
- Cardio Diagnostics Holdings, Inc. research and development expense for fiscal 2025 was $641.21K, a 181.28% increase from fiscal 2024.
- Cardio Diagnostics Holdings, Inc. research and development expense for fiscal 2024 was $227.97K, a 57.02% increase from fiscal 2023.
- Cardio Diagnostics Holdings, Inc. research and development expense for fiscal 2023 was $145.18K, a 258.93% increase from fiscal 2022.
- Cardio Diagnostics Holdings, Inc. research and development expense for fiscal 2022 was $40.45K, a 28.54% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $162.93K 10-Q · filed 2026-08-07 | $292.70K 10-Q · filed 2026-08-07 | $579.57K derived: sum of 3 quarters · filed 2026-08-07 | $768.62K derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2026-03-31 | $129.78K 10-Q · filed 2026-05-15 | $416.64K derived: sum of 2 quarters · filed 2026-05-15 | $605.69K derived: sum of 3 quarters · filed 2026-05-15 | $784.23K derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-12-31 | $286.87K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $475.92K derived: sum of 2 quarters · filed 2026-03-13 | $654.45K derived: sum of 3 quarters · filed 2026-08-07 | $641.21K 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $189.05K 10-Q · filed 2025-11-12 | $367.58K derived: sum of 2 quarters · filed 2026-08-07 | $354.35K 10-Q · filed 2025-11-12 | $690.97K derived: sum of 4 quarters · filed 2026-08-07 | |||
| 2025-06-30 | $178.54K 10-Q · filed 2026-08-07 | $163.10K 10-Q · filed 2025-08-14 | $297.32K 10-Q · filed 2026-08-07 | $165.30K 10-Q · filed 2025-08-14 | $501.92K derived: sum of 3 quarters · filed 2026-08-07 | $507.17K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $118.78K 10-Q · filed 2026-05-15 | $2.20K 10-Q · filed 2025-05-15 | $323.38K derived: sum of 2 quarters · filed 2026-05-15 | $328.63K derived: sum of 3 quarters · filed 2026-05-15 | $335.91K derived: sum of 4 quarters · filed 2026-05-15 | ||
| 2024-12-31 | $204.60K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $209.85K derived: sum of 2 quarters · filed 2026-03-13 | $217.13K derived: sum of 3 quarters · filed 2026-03-13 | $227.97K 10-K · filed 2026-03-13 | $29.13K 10-K · filed 2025-03-20 | ||
| 2024-09-30 | $5.25K 10-Q · filed 2025-11-12 | $12.53K derived: sum of 2 quarters · filed 2025-11-12 | $23.37K 10-Q · filed 2025-11-12 | $30.86K derived: sum of 4 quarters · filed 2025-11-12 | |||
| 2024-06-30 | $7.28K 10-Q · filed 2025-08-14 | $18.12K 10-Q · filed 2025-08-14 | $25.61K derived: sum of 3 quarters · filed 2025-08-14 | $64.32K derived: sum of 4 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $10.84K 10-Q · filed 2025-05-15 | $18.33K derived: sum of 2 quarters · filed 2025-05-15 | $57.04K derived: sum of 3 quarters · filed 2025-05-15 | $69.36K derived: sum of 4 quarters · filed 2025-05-15 | |||
| 2023-12-31 | $7.49K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $46.20K derived: sum of 2 quarters · filed 2025-03-20 | $58.52K derived: sum of 3 quarters · filed 2025-03-20 | $145.18K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $38.71K 10-Q · filed 2024-11-13 | $51.02K derived: sum of 2 quarters · filed 2024-11-13 | $137.69K 10-Q · filed 2024-11-13 | $168.78K derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $12.32K 10-Q · filed 2024-08-12 | $98.98K 10-Q · filed 2024-08-12 | $130.07K derived: sum of 3 quarters · filed 2024-08-12 | $133.26K derived: sum of 4 quarters · filed 2024-08-12 | |||
| 2023-03-31 | $86.67K 10-Q · filed 2024-05-15 | $117.75K derived: sum of 2 quarters · filed 2024-05-15 | $120.94K derived: sum of 3 quarters · filed 2024-05-15 | $125.98K derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $31.09K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $34.28K derived: sum of 2 quarters · filed 2024-04-01 | $39.32K derived: sum of 3 quarters · filed 2024-04-01 | $40.45K 10-K · filed 2024-04-01 | |||
| 2022-09-30 | $3.19K 10-Q · filed 2023-11-13 | $8.23K derived: sum of 2 quarters · filed 2023-11-13 | $9.36K 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $5.04K 10-Q · filed 2023-08-14 | $6.17K 10-Q · filed 2023-08-14 | |||||
| 2022-03-31 | $1.13K 10-Q · filed 2023-05-15 | ||||||
| 2021-12-31 | $31.47K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |